Growth & profitability
- Revenue has grown 12.0% per year over the past 5 years.
- Operating margin has contracted, at -5937.0% in the latest year.
Financial health
- Operating income covered interest expense -114.8× in the latest year.
SILO Financials Silo Pharma, Inc.
14 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $72102 | -$4M | 38.6% | -5937.0% | — | — | $5M |
| 2024 | $72102 | -$4M | 91.9% | -6526.4% | — | — | $4M |
| 2023 | $72102 | -$4M | 91.9% | -5347.4% | — | — | $4M |
| 2022 | $72102 | -$4M | 91.9% | -5031.3% | — | — | $11M |
| 2021 | — | $4M | — | — | — | — | $10M |
| 2020 | $40923 | -$3M | -330.4% | -5380.2% | — | — | $1M |
| 2019 | $40569 | -$1M | 32.5% | -2293.4% | — | — | $111752 |
| 2018 | — | -$969463 | — | — | — | — | $336679 |
| 2017 | — | $356536 | — | — | — | — | $294591 |
| 2013 | — | -$1M | — | — | — | — | $1M |
| 2013 | — | -$1M | — | — | — | — | $368682 |
| 2013 | — | -$1M | — | — | — | — | $10096 |
| 2012 | — | -$39446 | — | — | — | — | $279 |
| 2011 | — | -$49803 | — | — | — | — | $1752 |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $18026 | -$2M | -14.8% | -8846.4% | — | — | $4M |
| Dec '25 | $18026 | -$881530 | -14.8% | -4363.3% | — | — | $5M |
| Sep '25 | $18025 | -$1M | -14.8% | -6388.2% | — | — | $4M |
| Jun '25 | $18025 | -$1M | 91.9% | -6926.8% | — | — | $4M |
| Mar '25 | $18026 | -$1M | 91.9% | -6069.7% | — | — | $3M |
| Dec '24 | $18026 | -$2M | 91.9% | -10059.6% | — | — | $4M |
| Sep '24 | $18025 | -$928814 | 91.9% | -5603.6% | — | — | $5M |
| Jun '24 | $18025 | -$931779 | 91.9% | -5563.2% | — | — | $5M |
| Mar '24 | $18026 | -$801667 | 91.9% | -4879.1% | — | — | $3M |
| Dec '23 | $18026 | -$1M | 91.9% | -6455.8% | — | — | $4M |
| Sep '23 | $18025 | -$660160 | 91.9% | -4290.7% | — | — | $199839 |
| Jun '23 | $18025 | -$1M | 91.9% | -6185.8% | — | — | $158832 |
| Mar '23 | $18026 | -$906396 | 91.9% | -4457.4% | — | — | $5M |
| Dec '22 | $18026 | -$2M | 91.9% | -9192.0% | — | — | $11M |
| Sep '22 | $18025 | -$983246 | 91.9% | -5265.8% | — | — | $12M |
| Jun '22 | $18025 | -$658402 | 91.9% | -2742.2% | — | — | $9M |
| Mar '22 | — | -$604072 | — | — | — | — | $9M |
| Dec '21 | — | -$1M | — | — | — | — | $10M |
| Sep '21 | — | $6M | — | — | — | — | $10M |
| Jun '21 | $68085 | -$461990 | 24.3% | -641.6% | — | — | $4M |
Valuation over time
How the market has priced SILO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 467.0× (Mar '23) to 1297.2× (Jun '26).
P/S
Frequently asked questions
Is SILO growing its revenue and profit?
Over the past 5 years, Silo Pharma, Inc.'s revenue has grown 12.0% per year. These are computed facts, not advice.
How much debt does SILO have?
As of FY2025, Silo Pharma, Inc. reported — of total debt against $5M of cash; operating income covered interest expense -114.8×.
What is SILO's profit margin?
In FY2025, gross margin was 38.6%, operating margin -5937.0%, and net margin -5863.5%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.